

6 Referenzen

- ¹ Distler A. Hypertonie. In: Gross/ Schölmerich/ Gerok (Hrsg.): *Die Innere Medizin*. Stuttgart: Schattauer; 1996: 5.
- ² Dahl LK, Heine M, Tassinari L. Effects of chronic excess salt ingestion. Evidence that genetic factors play an important role in susceptibility to experimental hypertension. *J Exp Med*, 1962 Jun 1;115:1173-90.
- ³ Obiefuna PCM, Ebeigbe AB, Sofola OA, Aloamaka CP. Altered responses of aortic smooth muscle from Sprague-Dawley rats with salt- induced hypertension. *Clin. Exp. Pharmacol. Physiol.* 1991; 18: 813-818
- ⁴ Adviye E. Hypertension in black patients: an emerging role of the endothelin system in salt-sensitive hypertension. *Hypertension* 2000; 36(1) 62-7. Review.
- ⁵ Cooper ES, Kuller LH, Saunders E, Martinez-Maldonado M, Caplan LR, Yatsu FM, Savage DD, Curry CL, Yu PN, Shulman NB, Hall WD. Cardiovascular diseases and stroke in African-Americans and other racial minorities in the United States: a statement of health professionals. *Circulation* 1991; 83:1462–1480.
- ⁶ Fray JCS: Pathophysiology of Hypertension in Blacks. *New York, NY: Oxford University Press*; 1993.
- ⁷ Ergul S, Parish CD, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. *Hypertension* 1996; 28: 652-655.
- ⁸ Murphy JK, Alpert BS, Moes DM, Somes GW. Race and cardiovascular reactivity: a neglected relationship. *Hypertension* 1986; 23: 8-12.
- ⁹ Schiffrin EL: Endothelin: role in hypertension. *Biol Res.*1998;1931:199-208.
- ¹⁰ Benigni A: Endothelin antagonists in renal disease. *Kidney Int.* 2000;1957:1778-1794
- ¹¹ Lariviere R, Day R, Schiffrin EL. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. *Hypertension* 1993;1921:916-920.

- ¹² Barton M, d'Uscio LV, Shaw S, Meyer P, Moreau P, Lüscher TF. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. *Hypertension* 1998;1931:499-504
- ¹³ Rothermund L, Yagil Y, Yagil C, Traupe T, Neumayer HH, Paul M, Kreutz R. Selective ET_A-Receptor Antagonism Attenuates the Hypertensive Response to Salt and Target Organ Damage in the Sabra Experimental Model of Salt-Sensitive Genetic Hypertension. *J Am Soc Nephrol*. 1999; 10: Abstract 1789
- ¹⁴ Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature* 1988; 332: 411-5
- ¹⁵ Ames R S et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. *Nature*. 1999 ; 401(6750): 282-6
- ¹⁶ Inoue A, Yanagisawa M, Kimura S et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. *Proc Natl Acad Sci. USA* 1989; 86: 2863- 7
- ¹⁷ Yanagisawa M, Masaki T. Molecular biology and biochemistry of the endothelins. *Trends in Pharmacological Sciences*. 1989; 10: 374-8
- ¹⁸ Simonson MS. Endothelins: Multifunctional renal peptides. *Physiol. Rev.* 1993; 73: 375-411
- ¹⁹ Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology and pathology. *J Pharmacol Rev* 1994; 45: 325-415
- ²⁰ Xu D, Emoto N, Giaid A, Glaugter C, Kaw S, deWit D, Yanagisawa M. ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. *Cell*. 1994; 78: 473-485
- ²¹ Emoto N, Yanagisawa M. Endothelin-converting-enzyme-2 is a membrane-bound phosphoramidon-sensitive metalloprotease with acidic pH optimum. *J Biol. Chem.* 1995; 270: 15262-15268

- ²² Lüscher TF, Oemar BS, Boulanger CM, Hahn WA. Molecular and cellular biology of endothelin and its receptors- Part I. *J. Hypertension* 1993; 11: 7-11
- ²³ Lüscher TF, Oemar BS, Boulanger CM, Hahn WA. Molecular and cellular biology of endothelin and its receptors- Part II. *J. Hypertension* 1993; 11: 121-6
- ²⁴ Lovenberg W, Miller RC. Endothelin: A review of its effects and possible mechanisms of action. *Neurochem. Res.* 1990; 15: 407-17
- ²⁵ Kohan DE. Production of endothelin-1 by rat mesangial cells: Regulation by tumor necrosis factor. *J Lab. Clin. Med.* 1992; 119: 477-484
- ²⁶ Lüscher TF, Wenzel RR. Endothelin and endothelin antagonists: pharmacology and clinical implications. *Agents Actions Suppl.* 1995;45:237-53
- ²⁷ Bakris GL, Fairbanks LR, Traish AM. Arginine vasopressin stimulates human mesangial cell production of endothelin. *J Clin. Invest.* 1991; 87: 1158-1164
- ²⁸ Marsden PA, Dorfman DM, Collins T, Brenner BM, Orkin SH, Ballermann BJ. Regulated expression of endothelin 1 in glomerular capillary endothelial cells. *Am. J Physiol.* 1991; 261(1 Pt 2):F117-25.
- ²⁹ Kanse SM, Takahashi K, Lam HC, Rees A, Warren JB, Prota M, Molitatti P, Ghatel M, Bloom SR. Cytokine stimulated endothelin release from endothelial cells. *Life Science* 1991; 48: 1379-1384
- ³⁰ Hocher B, Thoene-Reineke C, Bauer C, Raschak M, Neumayer HH. The paracrine endothelin system: Pathophysiology and implications in clinical medicine. *Eur J. Clin. Chem. Clin. Biochem.* 1997; 35: 175-89
- ³¹ Webb DJ. Endothelin: From molecule to man. *Br. J. Clin. Pharmacol.* 1997; 44: 9-20
- ³² Saijonmaa O, Ristimäki A, Fyrquist F. Atrial natriuretic peptide, nitroglycerine and nitroprusside reduce basal and stimulates endothelin production from cultured endothelial cells. *Biochem. Biophys. Res. Commun.* 1990; 173: 514-20

- ³³ Hosoda K, Nakao K, Tamura N, Arai H, Ogawa Y, Suga S, Nakanishi S, Imura H. Organization, structure, chromosomal assignment and expression of the gene encoding the human endothelin-A receptor. *J. Biol. Chem.* 1992; 267: 18797-18804
- ³⁴ Masaki T. Possible role of endothelin in endothelial regulation of vasotone. *Annu. Rev. Pharmacol. Toxicol.* 1995; 235-255
- ³⁵ Warner TD, Mitchell JA, de Nucci G, Vane JR. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. *Cardiovasc. Pharmacol.* 1989; 13: S85-S88
- ³⁶ Hirata Y, Emori T, Eguichi S, Kanno K, Imai T, Ohta K, Marumo F. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. *J Clin. Invest.* 1993; 91: 1367-1372
- ³⁷ Alberts GF, Peifley KA, Johns A, Kleha JF, Winkles JA. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. *J. Biol. Chem.* 1994; 269: 10112-10118
- ³⁸ Mizuguchi T, Nishiyama M, Moroi K, Tanaka H, Saito T, Masuda Y, Masaki T, de Wit D, Yanagisawa M, Kimura S. Analysis of two pharmacologically predicted endothelin B receptor subtypes by using the endothelin B receptor knockout mouse. *Br. J. Pharmacol.* 1997; 120: 1427-30
- ³⁹ Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. *Nature* 1990; 348: 730-732
- ⁴⁰ Sakurai T, Yanagisawa M, Takawa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. *Nature* 1990; 732-5
- ⁴¹ Hosoda K, Nakao K, Arai H, Suga S, Ogawa Y, Mukoyama M, Shirakami G, Saito Y, Nakanishi S, Imura H. Cloning and expression of human endothelin-1 receptor cDNA. *FEBS Letters* 1991; 287: 23-26

- ⁴² Simonson MS, Dunn MJ. Cellular signaling by peptides of the endothelin gene family. *FASEB J.* 1990; 2989-3000
- ⁴³ Masaki T, Yanagisawa M, Goto K. Physiology and pharmacology of endothelins. *Med. Res. Rev.* 1992; 12 (4): 391-421
- ⁴⁴ Rabelink TJ, Kaasjager KAH, Boer P, Stroes EG, Braam B, Koomans HA. Effects of endothelin-1 on renal function in humans: Implications for physiology and pathophysiology. *Kidney Int.* 1994; 46: 376-381
- ⁴⁵ Kaasjager KAH, van Rijn HJM, Koomans HA, Rabelink TJ. Interactions of nifedipine with the renovascular effects of endothelin in humans. *J. Pharmacol. Exp. Ther.* 1995; 275: 306-311
- ⁴⁶ Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC, Brown JH, Chien KR. Endothelin induction of inositol phospholipid hydrolysis, sacromere assembly and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. *J. Biol. Chem.* 1990; 265(33): 20555-20562
- ⁴⁷ Clozel M, Gray GA, Breu V, Loffler BM, Osterwalder R. The ET_B-Receptor mediates both vasodilatation and vasoconstriction in vivo. *Biochem. Biophys. Res. Commun.* 1992; 186: 867-73
- ⁴⁸ Kasuya Y, Takuwa Y, Yanagisawa M, Kimura S, Goto K, Masaki T. Endothelin-1 induces vasoconstriction through two functionally distinct pathways in porcine coronary artery: Contribution of phosphoinositide turnover. *Biochem. Biophys. Res. Commun.* 1989; 161: 1049-55
- ⁴⁹ Griendling KK, Tsuda T, Alexander RW. Endothelin stimulates diacylglycerol accumulation and activates protein kinase C in cultured vascular smooth muscle cells. *J. Biol. Chem.* 1989; 264: 8237-40
- ⁵⁰ Bloom ITM, Bentley FR, Wilson MA, Garrison RN. In vivo effects of endothelin on the renal microcirculation. *J. Surg. Res.* 1993; 54: 274-280

- ⁵¹ Rakugi H, Nakamaru M, Saito H, Nigaki J, Ogihara T. Endothelin inhibits renin release from isolated rat glomeruli. *Biochem. Biophys. Res. Commun.* 1988; 155:1244-47
- ⁵² Goetz K, Wang BC, Leadley R, Zhu JL, Madwed J, Bie P. Endothelin and sarafatoxin produce dissimilar effects on renal blood flow, but both block the antidiuretic effects of vasopressin. *Proc. Soc. Exp. Biol. Med.* 1989; 191: 425-27
- ⁵³ Ishikawa T, Yanagisawa M, Kimura S, Goto K, Masaki T. Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria. *Am. J. Physiol.* 1988; 255: H 970-73
- ⁵⁴ Fukuda Y, Hirata Y, Yoshimi H, Kojima T, Kobayashi Y, Yanagisawa M, Masaki T. Endothelin is a potent secretagogue for atrial natriuretic peptide in cultured rat atrial myocytes. *Biochem. Biophys. Res. Commun.* 1988; 155: 167-72
- ⁵⁵ Mascia L, Fedorko L, Stewart DJ, Mohamed F, terBrugge K, Ranieri VM, Wallace MC. Temporal relationship between endothelin-1 concentrations and cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. *Stroke* 2001; 32(5):1185-90
- ⁵⁶ Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink JR, Frey A, Rainisio M, Kobrin I. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. *J. Am. Coll. Cardiol.* 2003; 42: 784-790
- ⁵⁷ Kohan DE. Endothelins in the normal and diseased kidney. *Am J Kidney Dis.* 1997;29:2-26
- ⁵⁸ Remuzzi G, Benigni A. Endothelins in the control of cardiovascular and renal function. *Lancet* 1993; 342: 589-93
- ⁵⁹ Rettig R, Schmitt B. Experimental hypertension following kidney transplantation in the rat. *Handbook of Hypertension, Vol. 16: Experimental and Genetic Models of Hypertension* Hrsg.: D. Ganten and W. de Jong 1994; Elsevier Sciences BV; 6: 141-154

- ⁶⁰ Yamori Y. Development of the spontaneously hypertensive rat (SHR), the stroke-prone SHR (SHRSP) and their various substrain models for hypertension-related cardiovascular diseases. *Handbook of Hypertension, Vol. 16: Experimental and Genetic Models of Hypertension* Hrsg.: D. Ganten and W. de Jong 1994; Elsevier Sciences BV; 15: 346-360
- ⁶¹ Smirk FH, Hall WH. Inherited hypertension in rats. *Nature* 1958; 182: 727-728
- ⁶² Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. *Jpn Circ J.* 1963; 27: 282-93
- ⁶³ Yamori Y, Tomimoto K, Ooshima A, Hazama F, Okamoto K. Proceedings: Developmental course of hypertension in the SHR-substrains susceptible to hypertensive cerebrovascular lesions. *Jpn Heart J.* 1974 Mar;15(2):209-10
- ⁶⁴ Orth SR, Esslinger JP, Amann K, Schwarz U, Raschack M, Ritz E. Nephroprotection of an ET(A)-receptor blocker (LU 135252) in salt-loaded uninephrectomized stroke-prone spontaneously hypertensive rats. *Hypertension* 1998;1931:995-1001
- ⁶⁵ Goldsby, R.A., Kindt, T.J., Osborne, B.A. & Kubly, J. Enzyme-Linked Immunosorbent Assay. In *Immunology*, 5te Aufl. (1926), pp. 148-150. Freeman, New York 2003.
- ⁶⁶ Bradford, M. M. A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding. *Anal. Biochem.* 1976; 72:248-254
- ⁶⁷ Scatchard G, Note on the equation of state explicit in the volume. *Proc Natl Acad Sci USA.* 1930 16(12): 811–813
- ⁶⁸ Hoher B, George I, Rebstock J, Bauch A, Schwarz A, Neumayer HH, Bauer C. Endothelin system-dependent cardiac remodeling in renovascular hypertension. *Hypertension* 1999;1933:816-822
- ⁶⁹ Alwine JC, Kemp DJ, Stark GR. Method for detection of specific RNAs in agarose gels by transfer to diazobenzyloxymethyl-paper and hybridization with DNA probes. *Proc Natl Acad Sci U S A.* 1977 Dec;74(12):5350-4.

- ⁷⁰ Schunkert H, Orzechowski HD, Bocker W, Meier R, Riegger GA, Paul M. The cardiac endothelin system in established pressure overload left ventricular hypertrophy. *J Mol Med.* 1999; 1977:623-630
- ⁷¹ Raij L, Azar S, Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. *Kidney Int.* 1984;1926:137-143
- ⁷² Veniant M, Heudes D, Clozel JP, Bruneval P, Menard J. Calcium blockade versus ACE inhibition in clipped and unclipped kidneys of 2K-1C rats. *Kidney Int.* 1994; 1946: 421-429
- ⁷³ Barton M, Vos I, Shaw S, Boer P, D'Uscio LV, Grone HJ, Rabelink TJ, Lattmann T, Moreau P, Lüscher TF. Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis. *J Am Soc Nephrol.* 2000; 11: 835-485
- ⁷⁴ Benigni A, Perico N, Gaspari F, Zoja C, Bellizzi L, Gabanelli M, Remuzzi G. Increased renal endothelin production in rats with reduced renal mass. *Am.J.Physiol* 1991;260:F331-F339
- ⁷⁵ Orisio S, Benigni A, Bruzzi I, Corna D, Perico N, Zoja C, Benatti L, Remuzzi G. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. *Kidney Int.* 1993;1943:354-358
- ⁷⁶ Lariviere R, Lebel M, Kingma I, Grose JH, Boucher D. Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass. *Am J Hypertens.* 1998; 11(8 Pt 1): 989-97
- ⁷⁷ Pollock DM, Allcock GH, Krishnan A, Dayton BD, Pollock JS. Upregulation of endothelin B receptors in kidneys of DOCA-salt hypertensive rats. *Am.J.Physiol Renal Physiol.* 2000; 278: F279-F286
- ⁷⁸ Matsumura Y, Kuro T, Konishi F, Takaoka M, Garipey CE, Yanagisawa M. Enhanced blood pressure sensitivity to DOCA-salt treatment in endothelin ET(B) receptor-deficient rats. *Br J Pharmacol.* 2000;129:1060-1062

- ⁷⁹ Gariépy CE, Willaims JA, Richardson JA, Yanagisawa M. Salt-sensitive Hypertension in Endothelin-B-receptor-deficient rats. *Sixth International Conference on Endothelin October 10-13, 1999*. Montreal, Canada, Abstract 011
- ⁸⁰ Ohuchi T, Laghmani K, Yamada T, Gariépy CE, Preisig PL, Alpern RI, Yanagisawa M. Salt-Sensitive Hypertension in endothelin-B-receptor-deficient mice due to impaired renal salt excretion. *Sixth International Conference on Endothelin October 10-13, 1999*. Montreal, Canada, Abstract 010
- ⁸¹ Gallego MS, Ling BN. Regulation of amiloride-sensitive Na⁺ channels by endothelin-1 in distal nephron cells. *Am J Physiol*. 1996;271:F451-F460
- ⁸² Benigni A, Perico N, Remuzzi G. Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression. *Nephrologie and Hypertension* 2001; 10: 1-6